22 August 2024 - Shanghai Henlius Biotech announced that the company's business partner, Accord Healthcare has received marketing approval (Notice of Compliance) from the Health Canada for HLX02 (Hanquyou in China, Hercessi in US, Zercepac in Europe), a trastuzumab biosimilar self-developed and manufactured by Henlius. 

The product has been approved under the trade name of Adheroza in Canada for the treatment of early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Read Henlius press release